PDS Biotech Embarks on VERSATILE-003 Phase 3 Clinical Trial
PDS Biotechnology Corporation (NASDAQ: PDSB) has announced an exciting new chapter in its efforts to combat cancer with the initiation of the VERSATILE-003 Phase 3 clinical trial. The company, recognized for its innovative immunotherapy approaches, is now opening doors for patient enrollment. This milestone marks a significant step towards providing new treatment options for patients facing HPV16-positive head and neck cancer.
A New Era in Cancer Treatment
“Today, we are excited to announce the first trial site is operational, and we continue to activate additional clinical centers,” stated Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. He underscored the momentum gained from previous studies, particularly the VERSATILE-002 study, which showcased promising clinical responses. This confidence fuels the ambition behind the registrational trial and reflects a robust commitment to enhancing patient outcomes.
Details of the VERSATILE-003 Trial
VERSATILE-003 is a comprehensive global study characterized as a multi-center, randomized, controlled, and open-label Phase 3 pivotal trial. It aims to assess the safety and efficacy of Versamune® HPV in combination with pembrolizumab, a standard immune checkpoint inhibitor, as a first-line treatment for patients with recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). The trial plans to enroll roughly 350 participants split between the experimental and the control arm, with an allocation ratio of 2:1 to the latter, receiving pembrolizumab alone.
The primary goal of the trial centers on overall survival rates, while secondary objectives will delve into factors such as objective response rate, progression-free survival, disease control rate, and the duration of response to the treatment.
Meet the Principal Investigator
Leading the charge in this trial is Dr. Katharine Price, an esteemed Associate Professor of Oncology at the Mayo Clinic Comprehensive Cancer Center, who will serve as the Principal Investigator. Her expertise in oncology and solid commitment to improving treatment modalities make her a vital asset to this groundbreaking research.
Optimism for Patient Outcomes
Dr. Kirk Shepard, Chief Medical Officer at PDS Biotech, expressed optimism about the trial’s potential, stating, “Advancing to Phase 3 represents a crucial milestone for us. We believe that the combination of Versamune® HPV and pembrolizumab can significantly enhance the immune response and offer substantial clinical benefits to patients.” Such optimism is pivotal in providing hope to those battling this challenging disease.
Exploring the Mechanism of Versamune® HPV
Versamune® HPV is a specialized immunotherapy that stimulates T cells specifically targeting HPV. Administered via subcutaneous injection, this innovative treatment aims to provoke a robust immune response against HPV16 by activating various immune pathways. This approach is particularly important as it paves the way for new avenues in cancer immunotherapy.
Following promising results from the VERSATILE-002 trial, the U.S. Food and Drug Administration granted Versamune® HPV Fast Track designation, an essential step towards facilitating access to this potentially life-saving therapy once Biologics License Application (BLA) is submitted.
About PDS Biotechnology
PDS Biotech is a leader in the realm of immunotherapy, dedicated to reshaping approaches to cancer treatment. Their ongoing clinical trials expand the horizons of what is possible for advanced HPV16-positive head and neck squamous cell cancers, with Versamune® HPV standing at the forefront of this initiative. The company is committed not only to enhancing existing therapies but also to exploring additional combinations, such as the integration of PDS01ADC, an IL-12 fused antibody drug conjugate (ADC) alongside standard-care treatments.
For more details on VERSATILE-003 and the ongoing developments, please refer to ClinicalTrials.gov for important information related to the trial.
Frequently Asked Questions
What is the VERSATILE-003 Phase 3 Trial?
The VERSATILE-003 trial aims to evaluate the safety and efficacy of Versamune® HPV combined with pembrolizumab for HPV16-positive head and neck cancer.
When did the trial start?
The trial has officially launched and is open for patient enrollment at multiple sites.
Who is leading the trial?
Dr. Katharine Price from the Mayo Clinic Comprehensive Cancer Center is the Principal Investigator.
What outcomes is the trial measuring?
The primary endpoint is overall survival, while secondary endpoints include response rates and survival duration.
Is Versamune® HPV a recognized treatment?
Yes, it has received Fast Track designation from the FDA, highlighting its potential as a significant treatment option.
